No Data
Haoyuan Pharmaceutical: 2024 Annual Report of Shanghai Haoyuan Pharmaceutical Co., Ltd. (updated)
Shanghai Haoyuan Pharmaceutical Co., Ltd. 2024 Annual Report (updated)
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Haoyuan Pharmaceutical: Summary of the 2024 Annual Report of Shanghai Haoyuan Pharmaceutical Co., Ltd.
Haoyuan Pharmaceutical: 2024 Annual Report of Shanghai Haoyuan Pharmaceutical Co., Ltd.
Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) P/E Is Still On The Mark Following 31% Share Price Bounce